By Melissa Diaz, CPA
Right now the peptide world is watching one calendar. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee meets to vote on whether seven peptides belong on the 503A bulks list. BPC-157 is on the docket. So are TB-500, KPV, MOTS-c, and a few others. If you run a peptide business, you already have this date circled.
But here’s the thing most founders miss. A yes vote does not mean you can sell anything. Not this year. Maybe not next year either.
A favorable vote is a starting line, not a finish line
Say the committee recommends all seven. That would be great news. It would also be the easy part. After a positive recommendation, the FDA still has to write a proposed rule, open a public comment period, and then publish a final rule. That whole process takes time. Most analysts put realistic pharmacy availability in early 2027 at the soonest, and plenty of them say later.
You could get the best possible outcome this month and still be a year or more away from legal compounding revenue. That gap is where a lot of peptide businesses get into trouble with investors.
And the vote itself is not a lock. Back in 2024, the committee voted against nearly every peptide it reviewed. The FDA follows those recommendations most of the time, but most of the time is not always. So the range of outcomes is wide, and the timeline is fuzzy.
Why one model isn’t enough
Picture a founder walking into a raise with a single financial model. It assumes a clean yes vote, fast rulemaking, and revenue starting next quarter. What does a sharp investor think when they see that?
They think you don’t understand your own market.
Investors in this space already know the rules are uncertain. They are not looking for a founder who pretends otherwise. They want to see that you have thought about what happens if the vote goes sideways, or if it passes but the final rule lands eighteen months out. A model built on one outcome tells them you got lucky with your assumptions, or you’re hoping nobody asks the hard question.
Build the model around the range
The fix is scenario planning, and it’s simpler than it sounds. You build three versions of the same model.
The first is favorable and fast. The vote passes, rulemaking moves quickly, and compounding revenue starts in early to mid 2027. The second is favorable but slow. Same yes vote, but the final rule drags, so your revenue timeline stretches and your cash has to cover the gap. The third is the hard one. The vote fails or stalls, and you’re back to research-use revenue and whatever demand exists while you wait for the next PCAC window.
The point isn’t to predict the future. It’s to show an investor you can survive more than one version of it.
Each scenario changes your numbers in ways that matter. Revenue timing shifts. Your runway shifts with it. The amount you need to raise, and when, depends entirely on which world you land in. When you can put all three side by side, you’re no longer guessing. You’re pricing the risk right into the plan.
Where a fractional CFO comes in
Here’s where I’ll be direct. Most early peptide companies don’t have someone in-house who can build this kind of layered model. And a founder juggling product, compliance, and fundraising usually doesn’t have the hours to do it well.
That’s the clean entry point for a fractional CFO. Not to run your books. To sit with the regulatory calendar, turn each scenario into real numbers, and hand you a model that holds up when an investor pushes on it. The uncertainty isn’t going away before your next raise. So the smart move is to build it into the plan on purpose, not to wish it away.
The founders who raise well in this market won’t be the ones who guessed the vote right. They’ll be the ones who showed up ready for every outcome.
Don’t wait. Reach out to High Rock Accounting today to connect with one of our peptide specialized fractional CFOs.
Melissa Diaz, CPA is a founder and principal at High Rock Accounting, where she works with peptide, life sciences, and cannabis operators on financial strategy and fractional CFO services.
Enjoyed this article? Consider Sharing
Author
